Jefferies: CSL's Lixudebart Licensing Deal Reflects Current R&D Strategy
Jefferies suggests that CSL's agreement with Alentis Therapeutics to jointly develop and market a rare kidney and liver disease treatment exemplifies the company's current research and development philosophy, which centers on acquiring assets to bolster its pipeline, according to analyst David Stanton.